newsfilter
← Latest News
GlobeNewswire·

Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

Reached broad alignment with the FDA on the registration path for CRB-701 for 2L treatment in head and neck squamous cell carcinoma (HNSCC) and cervical cancer with CRB-701Announced presentation of updated CRB-701 data